Join the Psoriatic Arthritis group to help and get support from people like you.
Psoriatic Arthritis News
Psoriasis, With or Without Psoriatic Arthritis, Associated With Fatigue
MONDAY, July 1, 2024 – Psoriasis is associated with fatigue, especially among those with psoriatic arthritis (PsA), according to a study published in the July issue of the Journal of the American...
FDA Expands Pediatric Indication for Rinvoq
FRIDAY, June 21, 2024 – The U.S. Food and Drug Administration has expanded indications for Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular...
Coexistence of Psoriatic Arthritis, Atopic Dermatitis May Offer Treatment Insights
MONDAY, May 13, 2024 – Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both conditions may mean special attention should be given to selecting optimal...
FDA Approves Selarsdi (ustekinumab-aekn), a Biosimilar to Stelara
REYKJAVIK, Iceland & PARSIPPANY, N.J.--(BUSINESS WIRE) April 16, 2024 --Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
FDA Approves Simlandi (adalimumab-ryvk), an Interchangeable Biosimilar to Humira
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 – Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory...
FDA Grants Interchangeable Designation to Pfizer’s Biosimilar Abrilada
NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Hum...
FDA Approves Novartis Cosentyx as First Intravenous (IV) Formulation Interleukin-17A Antagonist for Rheumatic Diseases
EAST HANOVER, N.J., Oct. 6, 2023 /PRNewswire/ – Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved an...
Model Predicts New Psoriatic Arthritis in People With Psoriasis
FRIDAY, Aug. 11, 2023 – The development of psoriatic arthritis (PsA) can be predicted with reasonable accuracy for psoriasis patients, according to a study published online Aug. 9 in Arthritis &...
Co-Occurrence of Psoriasis and Rheumatic Diseases Common
FRIDAY, Aug. 11, 2023 – Psoriasis is associated with rheumatic diseases, according to a study published online Aug. 5 in the Journal of the American Academy of Dermatology. Mimi Chung, from the...
FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira
JERSEY CITY, N.J.--(BUSINESS WIRE) May 24, 2023 --Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration ...
Stelara (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, Stelara provides a new therapeutic option for children six years of age and older living with active psoriatic...
Novartis Cosentyx Receives FDA Approval for the Treatment of Children and Adolescents with Enthesitis-Related Arthritis and Psoriatic Arthritis
- New approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across ...
FDA Approves Yusimry (adalimumab-aqvh), a Biosimilar to Humira
REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) appro...
Rinvoq (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
NORTH CHICAGO, Ill., Dec. 14, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib; 15 mg, once daily) for the t...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
prednisone, methotrexate, Humira, triamcinolone, cortisone, Enbrel, Remicade, Otezla, Xeljanz, view more... Stelara, Cosentyx, Skyrizi, adalimumab, dexamethasone, etanercept, Taltz